Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year.

百时美施贵宝（Bristol-Myers Squibb）前首席执行官乔瓦尼·卡福里奥（Giovanni Caforio）将成为诺华（Novartis）的下一任董事会主席。诺华于周二提名这位制药行业资深人士接替乔尔格·莱因哈特（Joerg Reinhardt）担任明年的职务。

Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025. The appointment of Caforio will be put to Novartis’ shareholders at the company’s annual general meeting. Announcement of the planned succession Tuesday came alongside first quarter earnings that beat Wall Street forecasts..

莱因哈特自2013年起担任诺华董事长，计划在2025年12年任期结束后退休。卡福里奥的任命将在诺华公司年度股东大会上提交给其股东。在周二宣布继任计划的同时，第一季度的收益超过了华尔街的预期。。

Caforio spent two decades at Bristol Myers, rising through the ranks to become the company’s CEO in 2015. Under his eight-year tenure as chief, Caforio oversaw a number of major acquisitions, most notably the $74 billion buyout of Celgene that greatly expanded Bristol Myers cancer drug business. More recently, the company agreed to pay $14 billion to acquire brain drug developer Karuna Therapeutics and its closely watched treatment for schizophrenia..

卡福里奥（Caforio）在百时美施贵宝（Bristol-Myers）工作了二十年，于2015年晋升为该公司首席执行官。在担任首席执行官的八年任期内，卡福里奥监督了多项重大收购，最引人注目的是斥资740亿美元收购Celgene，这大大扩展了百时美的抗癌药物业务。最近，该公司同意斥资140亿美元收购脑药开发商卡鲁纳治疗公司及其备受关注的精神分裂症治疗公司。。

He was replaced as Bristol Myers CEO by Chris Boerner in November.

11月，他被克里斯·博纳（ChrisBoerner）取代，成为百时美施贵宝（Bristol-Myers）首席执行官。

Reinhardt, meanwhile, started at Sandoz in 1982, joining Novartis via the 1996 merger of Sandoz and Ciba-Geigy. He held several executive positions, including chief operating officer and head of Novartis’ then vaccines and diagnostics division, before he was appointed board chair.

与此同时，莱因哈特于1982年在桑多斯（Sandoz）创业，1996年通过桑多斯（Sandoz）和汽巴盖伊（Ciba Geigy）的合并加入诺华。在被任命为董事会主席之前，他曾担任多个行政职位，包括首席运营官和诺华当时的疫苗和诊断部门负责人。

During his time as chair, Novartis switched CEOs and underwent a significant transformation. The drugmaker sold its consumer business to GSK for $13 billion in 2018 and spun out its eye business Alcon.

在担任主席期间，诺华更换了首席执行官，并经历了重大转变。2018年，这家制药商以130亿美元的价格将其消费业务出售给了葛兰素史克，并分拆了其眼科业务爱尔康。

The company shed its long-held stake in Roche in 2021 and later restructured its workforce and drug pipeline. Last year the company spun out Sandoz, completing the last major step in current CEO Vas Narasimhan’s plan to focus Novartis on high-margin prescription pharmaceuticals.

该公司于2021年放弃了长期持有的罗氏股份，随后重组了员工队伍和药品管道。去年，该公司分拆出Sandoz，完成了现任首席执行官Vas Narasimhan将诺华专注于高利润处方药的计划的最后一个重大步骤。